Načítá se...
End-stage renal disease reduces the expression of drug-metabolizing cytochrome P450s
BACKGROUND: End-stage renal disease is an irreversible status of kidney dysfunction that reduces both renal and non-renal drug clearance. Accumulation of uremic toxins seems to modify the activities of drug-metabolizing cytochrome P450 (CYP) enzymes. The aim of the present work was to refine gene ex...
Uloženo v:
| Vydáno v: | Pharmacol Rep |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer International Publishing
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7704481/ https://ncbi.nlm.nih.gov/pubmed/32638224 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s43440-020-00127-w |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|